Back to search results

A Study of ARC-02 in B-cell Non-Hodgkin Lymphoma

This study is looking into a new treatment called ARC-02, given as an intravenous (IV) infusion, for people with B-cell Non-Hodgkin Lymphoma (NHL). It also involves Rituximab, another IV infusion. The main goals are to see how safe ARC-02 is, how well your body handles it, and if it helps shrink the lymphoma. You might be able to join if you are 18 or older, have a confirmed diagnosis of B-cell NHL (like Follicular lymphoma, Marginal zone lymphoma, Mantle cell lymphoma, or Diffuse large B-cell lymphoma), and your disease can be measured. The study plans to enroll 140 participants, but its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 140 participants. The study will assess safety, tolerability, and preliminary effectiveness of ARC-02.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years to monitor for side effects and treatment response.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07691606

A Study of ARC-02 in B-cell NHL

Recruiting
PHASE1Ages 18+InterventionalTreatment
Taiho Oncology, Inc.
~140 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:ARC-02Rituximab

At a glance

Recruiting sites
2 of 29 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs)
Measured over Up to 5 years
+2 more outcomes measured

Conditions

B-cell Non Hodgkin Lymphoma

Explore related trials

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone Lymphoma

NCT07691606

Where you'd take part

This study runs at 29 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • ASST Papa Giovanni XXIII

    Bergamo, Italyno site contact published

    Not yet recruiting

  • Austin Health

    Melbourne, Australiano site contact published

    Not yet recruiting

  • Centre Hospitalier Universitaire de Lille (CHU Lille) - Hopital Claude Huriez

    Lille, Franceno site contact published

    Not yet recruiting

  • Centro di Riferimento Oncologico (CRO Aviano)

    Aviano, Italyno site contact published

    Not yet recruiting

  • CHU Nantes - Hotel Dieu

    Nantes, Franceno site contact published

    Not yet recruiting

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsinno site contact published

    Not yet recruiting

  • Gold Coast Hospital

    Southport, Australiano site contact published

    Not yet recruiting

  • Hopital Henri-Mondor

    Créteil, Franceno site contact published

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Taiho Oncology, Inc.
[email protected]
+1 844-878-2446
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs)Up to 5 years
  • Dose Escalation: Number of Participants with Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Up to 5 years
  • Dose Expansion: Objective Response Rate (ORR) as Assessed by the InvestigatorUp to 5 years